Drugs / TQD3524
last change Jul 2026 re-read 2 minutes ago

TQD3524

Developed for
bacterial pneumonia
Investigated by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07512596 Jul 2026 → Jul 2027 expected bacterial pneumonia Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06522945 Comparator Jul 2024 → Dec 2025 gram-negative bacterial infections Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TQD3524 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06522945
1

NCT07512596

Route Intravenous intravenous drip” NCT07512596